Written by Magnus Nossen
(with 2 important comments by Smith at the bottom)
- The patient's symptoms had started about 14 days prior to admission — but worsened significantly during the course of the last 24 hours.
- Previously healthy, taking no medication and exercising regularly.
- No anginal symptoms asymptomatic during physical exercise.
Figure-1: Today's initial ECG (Cabrera layout, paper speed 25mm/sec.). |
- During observation in the ED the patient had multiple self-terminating runs of Non-Sustained monomorphic Ventricular Tachycardia (NSVT).
- IV metoprolol boluses were administered without any effect on the ventricular ectopy. Potassium and magnesium serum levels were normal.
- Bedside echo was challenging simply due the frequency of ectopic beats — but did not reveal any pathology.
- A 150mg IV bolus of amiodarone was added to the IV metoprolol without any effect. Following this, an IV amiodarone infusion of 1200mg/24 hours was started.
How can you stabilize this patient? What will be your next measure?
You have given IV MgSO4 — a fast acting ß-blocker — and IV amiodarone bolus and infusion.
- The possibility of an ischemic cause of the ventricular arrhythmia has to be considered! That said — there were no clinical symptoms or ECG findings suggestive of ongoing ischemia. Troponin T was negative on admission and on repeat blood draw.
Therefore — A different approach is needed. There are 2 main options:
- Overdrive pacing could be considered — and in the right clinical situation, this is often effective for reducing ventricular arrhythmias (especially in the case of preventing pause induced or bradycardia-induced arrhythmias in association with QTc prolongation).
- Try a different kind of antiarrhythmic. This is what was done in today's case. The intricacies of the different classes of antiarrhythmics and their mechanism of action extend beyond the scope of this blog. I limit myself to the summarized overview in Figure-3 of antiarrhythmic agents and their principle site of action.
Figure-3: Vaughan-Williams Classification of antiarrhythmic agents. |
- IV lidocaine was given as a 100 mg bolus, followed by a continuous infusion. A few minutes after the bolus was administered, there was no more NSVT! In fact, after the bolus was completed — there were hardly any PVCs at all.
- The patient remained free of PVCs for several hours after the lidocaine was stopped.
- Echocardiography was done and was completely normal.
- The patient was loaded with 100mg IV flecainide.
Figure-4: Long lead II 3-minute rhythm strip after initiation of IV flecainide. PVCs and short runs of NSVT are extremely frequent for the first half of the recording. |
- The patient was transitioned to oral flecainide. He has since been free of PVCs.
- Below in Figure-5 — is a 10-minute continuous lead II recording on oral Flecainide, now showing sinus bradycardia without a single PVC!
Figure-5: Long lead II recording on oral flecainide (10 minutes of continuous recording — each line being 1-minute long). No PVCs are seen. |
- As noted above — echocardiography was completely normal.
- CT coronary angiogram showed a hypoplastic RCA and dominant LCx. There were no plaques or stenoses.
- Once the arrhythmia was under control — cardiac MRi was performed. The MRi was completely normal without any early or late enhancement and without any signs of arrhythmogenic cardiomyopathy.
- The patient has been scheduled for a PVC ablation procedure. This patient very likely has some form of idiopathic ventricular tachycardia.
- There are many different types of idiopathic VTs with the outflow tract ventricular tachycardias (OT-VT) being most common. Of the ventricular outflow tract tachycardias — (RVOT-VT) makes up 80-90%.
- Idiopathic VT is not limited to the outflow tract tachycardias however — as it can arise from other sites in the myocardium or conduction system. The list is extensive and includes but (but is not limited to) fascicular VT, annular VT, bundle branch VT and (what perhaps is the most likely diagnosis in todays case) — moderator band ventricular tachycardia.
- The axis is leftward and superior, with a predominantly positive QRS in lead I and negative QRS in the inferior leads.
- Given early involvement of the specialized conduction system — the QRS may be relatively narrow with a sharp upstroke. However, this is dependent on the exit site — and the QRS could be wide if the exit is closer to the RV free wall.
- Precordial transition is typically later than V4.
- The differential diagnosis, especially in younger patients, includes atriofascicular tachycardia also known as "Mahaim" tachycardia.
In patients with PVCs/VT and a presentation not typical for an idiopathic origin — cardiac magnetic resonance (CMR) should be considered, even if the Echo is normal.
- Beta-blockers, non-dihydropyridine calcium channel blockers, or flecainide should be considered when catheter ablation is not available, not desired, or is particularly risky.
- Catheter ablation or flecainide should be considered in symptomatic patients with idiopathic VT/PVCs from an origin other than the RVOT or the left fascicles. [1]
Considerations Regarding Use of Flecainide:
A 12-lead ECG is mandatory before starting therapy. It is reasonable to perform an echocardiogram to evaluate LV function. Flecainide displays use-dependence, whereby it blocks voltage-gated sodium channels more at higher heart rates. This is why exercise stress testing is sometimes performed to ensure the drug does not cause significant QRS prolongation or precipitate Brugada ECG pattern at higher heart rates.
In general, it is strongly suggested to test the first dose under medical observation. The minimum effective plasma concentration of flecainide is about 200 ng/mL. The optimal range is between 200 ng/mL and 400 ng/mL. This plasma concentration leads to a QRS prolongation of about 10 msec. A prolongation of 40 msec or more is associated with and increased probability of cardiovascular adverse effects.
Smith comment-1: The primary side-effect of flecainide is sudden death. So you must be VERY careful before initiating a patient on this medication. It is particularly dangerous in patients with low EF. In 2016, I doubled the number of night shifts and suddenly was having 10,000 PVCs per day, very distressingly symptomatic. After a normal stress echo and normal MRI, my electrophysiologist put me on Flecainide. Within 1/2 hour of taking one tablet, all PVCs completely disappeared. He then insisted that I do another stress test, and I got my heart rate to 173 without any QRS widening. He then was satisfied that I would be safe on flecainide. Not too long after that, I stopped doing night shifts altogether and did not need the flecainide any more!!
----See the Cardiac Arrhythmia Suppression Trial (CAST) trial: patients with low EF and many chronic PVCs were trialed on anti-dysrhythmics. Those whose PVC frequency decreased were randomized to Flecainide, Encainide, Moricizine, or Placebo. The patients who received the anti-dysrhythmic (compared to placebo) had far more sudden death.
Smith comment-2: Another adverse effect from flecainide is atrial flutter with 1:1 conduction (if you happen to go into atrial flutter, the flecainide slows the flutter rate such that it is slow enough to conduct throught the AV node at 1:1 — and you can end up with a ventricular rate of 220!! ). Therefore, many cardiologists routinely add an AV nodal blocker when they start a patient on flecainide.
See here: Narrow Complex Tachycardia at a Rate of 220
- Exclude contraindications such as structural heart disease; symptomatic bradycardia; 2nd-degree or high-degree AV block; QRS >120 msec.; and Brugada syndrome.
- Record an ECG and calculate the QRS duration.
- Administer a loading oral dose of 250 mg (200 mg if the weight is lower than 70 kg).
- At plasma concentration peak (after 90–120 min.) — record another ECG and calculate the QRS duration.
- If the QRS duration is increased by less than 20 msec. — prescribe 100mg twice daily or 200 mg once daily. Check ECG again after one week.
- If the QRS duration is increased between 20 and 40 msec., or is wider than 120 msec — prescribe 50 mg twice daily or 100 mg once daily. Check again the ECG after 5 days.
- If the QRS duration is increased more than 40 msec., or is wider than 130 msec., or a Brugada pattern is detected — consider flecainide as contraindicated in that patient.
- An exercise stress test while taking the drug can be performed ensure that the QRS does not increase further at higher heart rates (ie, as a result of flecainide's use-dependence).
References:
[1] 2022 ESC Guidelines for Ventricular Arrhythmias: Key Points - American College of Cardiology. (2022, September 2)
[2] Ward, R. C., Van Zyl, M., & DeSimone, C. V. (2023). Idiopathic ventricular tachycardia. Journal of Clinical Medicine, 12(3), 930.
[3] Lavalle, C. et. al. (2021). Flecainide How and When: A Practical guide in supraventricular arrhythmias. Journal of Clinical Medicine, 10(7), 1456.
- What is idiopathic VT?
- — Does this patient have idiopathic VT?
- — Why should we care if this is idiopathic VT?
- As per Dr. Nossen — over 80% of idiopathic VT cases are the result of RVOT VT. Fascicular VTs make up many of the remaining cases — with both of these forms being readily recognizable based on QRS morphology — and with both often responding to specific medical treatment (as per Figure-7 below).
- But not all forms of idiopathic VT are predictable based on their ECG appearance. Was today's case one of those unpredictable forms?
- Interesting features in this initial tracing included subtle underlying AV dissociation (PINK arrows highlighting the subtle deflections of partially-hidden on-time sinus P waves) — with periodic slight PR interval prolongation of some sinus-conducted beats due to "concealed" conduction following some PVCs (No evidence of AV block!).
- I thought QRS morphology of ventricular beats to be atypical for "idiopathic" VT in a patient ostensibly without underlying heart disease because: i) Ventricular beats are extremely wide (approaching 0.16 second in leads I,II,V5); and, ii) Although QRS morphology resembles LBBB conduction in the limb leads — the initial R wave in anterior chest leads is larger and wider than expected for LBBB conduction — and QRS morphology is bizarre in lateral chest leads V5,V6 (the vertical RED line highlighting onset of the QRS).
Figure-6: I've labeled the initial ECG in today's case. |
Underlying Heart Disease?
As per Dr. Nossen — evaluation included:
- A normal Echo.
- CT angiogram — showing a "hypoplastic" RCA and dominant LCx (with distinction between what is a "smaller" RCA in a left-dominant circulation vs an RCA with a lumen that is "too small" sometimes being difficult).
- Cardiac MRI — completely normal.
- Upcoming EP study (hopefully allowing for ablative VT treatment).
- Although rare — reduced lumen size of one or more coronary arteries has been reported as a cause of sudden death as its initial presentation in previously healthy young adults (See MacFarland et al — J Card Cases 4(3): E148-151, 2011 — and — Guo et al — JACC 17(18)- 2021).
- CLICK HERE — for my 8-minute Audio on Pearls for ECG Recognition of Idiopathic VT (with special attention to RVOT VT and Fascicular VT — which are the 2 most common forms).